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Prospective randomised trial of two dose levels of megestrol acetate in the
management of anorexia-cachexia syndrome in patients with metastatic
cancer
V Gebbia, A Testa and N Gebbia
Service ofChemotherapy, Policlinico, University ofPalermo, Italy.
S_ary Two doses of megestrol acetate (MA) have been prospectively compared in a random fashion as
treatment for cancer-related anorexia-cachexia syndrome (ACS) in 122 patients with progressive soft tissue
sarcoma, colorectal lung, head and neck and renal cancer resistant to systemic chemotherapy. After 30 days of
MA, 55% of patients receiving MA at 160 mg day-' reported an increase in appetite, 27% of patients no
variation and 18% complained of a decrease in appetite. Patients treated with MA at 320 mg day-' reported
an increase in appetite in 68% of cases, a stabilisation in 20% of cases and a decrease in 12%. Although an
increase in appetite was more frequently observed in patients receiving MA at 320 mg day-', however this
difference was not statistically significant (P =0.305). After 30 days ofMA, 31% ofpatients treated with MA at
160 mg day -showed an increasein body weight, 25% a stabilisation and 44% a decrease. In the group of
patients treated with MA at 320 mg day-l, 45% reported an increase in body weight, 16% no change and
23% weight loss. Although there was a trend favouring the higher dose of MA, overall analysis however failed
to detect any statistically significant difference between the two treatment arms (P=0.242). Twenty-seven
patients pretreated with 160 mg day- 'and 23 patients treated with 320 mg day-' received firtiher therapy with
MA at the dose of 320 and 480 mg day-' respectively. In the group of 22 patients treated with 320 mg day-',
four (18%) reported an increase in body weight, eight (36%) an improvement in appetite, but none had an
increase in performance status. Among the 20 evaluable patients treated with 480 mg day-', two (10%) had an
increase in body weight, four (20%) an improvement in appetite, but none reported an increase in performance
status. No difference in median survival was detected between the two arms. Toxicity was mild and predictable.
In conclusion, the data achieved in the present study confirm the clinical safety and effectiveness of oral MA in
the management of ACS in patients with advanced cancer resistant to systemic chemotherapy. Moreover, data
concening the dose escalation of MA dosage in unresponsive patients suggest that a step by step increase in
MA dosage could be the best way of administering MA for the management of ACS and that the increase of
MA dosage over 480 mg day-' will probably be useless in the vast majority of cases. Data on body weight
suggest that after 2 weeks' therapy MA could be stopped or its dosage tailored to patients' needs since the
majority of patients respond after only 15 days of MA.
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The anorexia-cachexia syndrome (ACS) is represented by a
severe wasting clinical condition characterised by anorexia
and progressive depletion of caloric reserve, body fat and
muscular tissues (De Wys, 1979). ACS is characteristic of
nearly 70% of patients with terminal neoplastic disease even
if it may be present also in earlier stages of tumour growth
(Brennan, 1981; De Wys, 1979; Tisdale, 1993). The
combination of anorexia and wasting is of great concern
for both patient and his/her family and therefore it is
important both physically and psychologically (De Wys,
1985). Moreover, patients with weight loss have a shorter
survival than those patients with stable weight. In fact, the
median survival of patients affected by breast, colorectal and
prostatic cancer without weight loss is approximately double
that of patients who lost weight (De Wys, 1985).
ACS usually develops progressively through a self-
maintaining cycle of anorexia, reduction in caloric intake,
muscle wasting and infections (Brennan and Burt, 1981;
Knox et al., 1983; Nixon et al., 1980; Young, 1977).
However, the biochemical mechanism underlying ACS is
still not well understood and most probably it is multi-
factorial. Recent experimental investigations have demon-
strated that circulating factors, such as TNF-z and -fi, IL-1,
IL-6 and y-IFN, may produce anorexia in animal models
through both a proteolytic/lipolytic mechanism and a direct
action on the hypothalamus (Beck and Tisdale, 1987; Lowry
and Moldawer. 1990; Ternell et al., 1987; Tisdale, 1993). The
most effective way of managing ACS would be an effective
reduction in tumour load, but this may be an elusive goal in
most cases since generally a significant proportion of patients
with ACS have already been heavily pretreated and thus
show a multidrug-resistant progressive neoplasm. Moreover,
systemic chemotherapy itself may contribute in some cases to
the worsening of anorexia probably via mechanisms different
from those underlying ACS (Boneterre et al., 1988; De Wys,
1979; Parnes and Aisner, 1992). Parenteral and/or enteral
hyperalimentation may improve caloric intake significantly in
patients with ACS, but to date there is no clear evidence that
this costly and often uncomfortable procedure eventually
results in an improvement in the patients' quality of life
(Parnes and Aisner, 1992).
The observation that appetite stimulation with significant
gain in body weight is often associated with hormonotherapy
with megestrol acetate in patients treated for prostatic
adenocarcinoma, metastatic breast cancer or malignant
melanoma has prompted several authors to explore the role
of MA in cancer anorexia and cachexia (Creagan et al., 1989;
Sedlacek, 1988; Tchekmedyian et al., 1986, 1992a; Splinter,
1992). A phase III trial of MA as first-line treatment for
metastatic breast cancer showed that weight gain increased
with MA dosage although objective tumour response rate
was not dose-related (Abrams et al., 1992). Thus, it is evident
that MA anabolic effect is entirely independent of the anti-
neoplastic activity of progestins, since these effects could also
be detected in patients affected by hormone-insensitive
malignant neoplasms. MA may have a true anabolic effect
in addition to stimulation of appetite: in fact the differentiat-
ing activity of MA on a preadipocyte fibroblast cell line in
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vitro has been shown to be dose-related and more potent than
that of dexamethasone (Hamburger et al., 1988). Moreover,
Loprinzi et al. (1993) have shown that megestrol-induced
weight increase stems primarily from an increase in body
mass, especially the adipose tissue, and that an increase in
body fluid accounted only for a minority of cases. MA
activity may be correlated to MA-induced inhibition of the
pituitary-adrenal axis inducing a reversible decrease of
plasma cortisol concentrations (Loprinzi et al., 1992).
The pharmacokinetic characteristics of MA are
particularly interesting especially if a rapid therapeutic
effect is desired. In fact the peak plasma concentration of
MA, equivalent to 218 pg ml-', is reached after only about
7 days of oral treatment at the dose of 160 mg day-' with
plateau plasma levels higher than those achieved with
1000 mg day-' of medroxyprogesterone acetate (Miller et
al., 1988).
In this paper we report the results of a prospective
randomised study of two different doses of MA in the
management of ACS. The trial was carried out with the aims
of evaluating if there was a dose-response effect and of
identifying if a further increase of MA dosage in
unresponsive patients could result in a positive effect on
appetite and body weight.
Patients and methods
Study design
Before entry into the study patients had to fulfil all the
following elegibility criteria; oral informed consent; diag-
nosis of non-hormone-dependent progressive cancer refrac-
tory to chemotherapy; age >,18 and <75 years;
performance status according to Karnofsky Index >50;
life-expectancy >3 months; weight loss >5%; absence of
brain metastases, obstructive disease, abdominal effusion or
peripheral oedema; no medical history of peptic ulcer, liver
cirrhosis, metabolic, thromboembolic or severe cardiovas-
cular diseases; geographical accessibility to the oncological
centre in order to guarantee a correct follow-up. Con-
comitant treatment with corticosteroids or androgens was
not permitted.
The calculation of sample size was based on the literature
data (Loprinzi et al., 1993) reporting a nearly 25% difference
in the percentage of patients who experienced appetite
stimulation at different dose levels of megestrol acetate.
Thus 120 patients had to be randomised to detect a 25%
difference in appetite stimulation between the two dose levels
at the significance level of x = 0.05 with an 80% power. The
aim of this open study was to test the effects of two different
dose levels of MA on weight, appetite, factors interfering
with food intake, performance status, pain, energy and
depression of patients affected by progressive cancer
refractory to systemic chemotherapy.
Treatment plan
Elegible patients were randomly assigned to receive (1) MA
160 mg day-' orally as a single tablet once a day, or (2) MA
320 mg day-' orally in two refracted doses 12 h apart.
Patients were stratified according to performance status
(60-70 vs 80-90) and severity of weight loss (<10% vs
, 10%). Appetite was evaluated using a Symptom Distress
Scale (SDS) from 1 to 5 grades. Body weight, appetite score,
Karnofsky Index, factors affecting food intake, as well as
tolerability were recorded at the time of randomisation and
after 15, 30, 60 and 90 days of therapy.
If, after 30 days of MA, weight gain or stabilisation of
weight but increase in appetite, MA dosage remained
unchanged up to 3 months of therapy if possible. If weight
loss or no change in both weight and appetite occurred, MA
dosage was increased from 160 mg day-' to 320 mg day-' in
arm 1, or from 320 to 480 mg day-' in arm 2. MA was
discontinued before completion of treatment if excessive
weight gain or unacceptable toxic reactions ensued. At each
follow-up visit, patients were carefully interviewed to assess
and monitor the type and severity of adverse events.
Before the beginning of treatment and every 2 weeks
patients had a complete physical examination, weight
determination, blood pressure examination, serum chemistry
tests, haemochromocytometrical analysis and were inter-
viewed also employing a written questionnaire to evaluate
appetite, food intake, nausea and other parameters.
Statistics
The chi-square contingency table was used for the analysis of
categorical variables. Student's t test was used for continuous
variables. Survival analysis was carried out according to the
Kaplan-Meier product limit analysis and the log-rank test
was used for statistical analysis of the differences between the
two survival curves.
Results
After approval by the ethics committee and fulfilling all the
entry criteria, a total of 122 patients with hormone-insensitive
advanced cancer were enrolled into the study. The main
demographic and clinical characteristics of enrolled patients
are depicted in Table I. The two groups of patients were
comparable in terms of sex and performance status
distribution, mean age, degree of weight loss, appetite and
other symptoms. In both arms there was a prevalence ofmale
patients over female ones. The mean percentages of weight
loss were 15.6% and 14.8% in group A and group B
respectively. More than 60% of patients had weight loss in
Table I Clinical characteristics of patients at entry
MA 160mgday-' MA 320mgdav-
No of enrolled patients
Mean age (range)
Sex (male/female)
Performance status
(Karnofsky index)
Mean
90
80
70
60
Weight loss (%)
Mean (range)
.110
<10
SDS score for appetite
Mean
0-1
2-3
4-5
Other symptoms
Pain
Low energy
Depression
Site of primary tumour
Lung
Colon rectum
Head/neck
Kidney
Sarcoma
Previous treatments
Surgery
Radiotherapy
Chemotherapy
62
63 years (46-75)
46/16
70.2
8
10
18
26
15.6 (5-30%)
41 (66%)
21 (34%)
3.1
9
30
23
23 (37%)
41 (66%)
36 (58%)
24
12
19
3
4
31 (50%)
46 (74%)
62 (100%)
60
65 years (50-77)
42 18
69.5
6
12
15
27
14.8% (5-28%)
37 (62%)
23 (38%)
2.9
7
32
21
18 (30%)
35 (58%)
39 (65%)
26
10
21
2
1
35 (58%)
43 (72%)
60 (100%)
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Table H Effect of MA on patients' subjective sense of appetite
(Symptom Distress Scale)
Megestrol acetate dose level
160mgda'-1 320mgday'
(no. ofpatients = 62) (no. ofpatients = 60)
Appetite No. % No. (%)
Decreased 11 (18) 07 (12)
Stable 17 (27) 12 (20)
Increased 34 (55) 41 (68)
Overall analysis P = 0.305. NS. Patients were evaluated after 30
days oftherapy with megestrol acetate.
excess of 10% in both treatment arms. Most patients had
lung, colorectal or head and neck carcinomas with a minority
of cases of renal carcinoma and soft tissue sarcoma. All
patients had previous systemic chemotherapy, but they were
off chemotherapy owing to refractory progressive disease.
Previous surgical and radiotherapeutic treatments were also
equally distributed between the two groups of patients.
The effects of the two doses of MA (160 vs 320 mg day-')
on patients' subjective sense of appetite are depicted in Table
II. After 30 days of therapy, 55% of patients receiving MA
160 mg day-' reported an increase in appetite, 27% of
patients no variation and 18% a decrease in appetite.
Patients treated with MA 320 mg day-' reported an increase
in appetite in 68% of cases, a stabilisation in 20% of cases
and a decrease in 12%. Although an increase in appetite was
more frequently observed in patients receiving MA
320 mg day-', this difference was not however statistically
significant (P=0.305).
Table III shows the effects of MA on body weight
according to the progestin dose levels and duration of
treatment. After 15 days of MA, an increase in body weight
was recorded in 27% of patients treated with MA
160 mg day-' and in 40% of patients receiving MA
320 mg day-'. After 30 days of MA, 31% of patients
treated with MA 160 mg day-' showed an increase in body
weight, 25% a stabilisation and 44% a decrease. On the other
hand, in the group of patients treated with MA
320 mg day-', 45% reported an increase in body weight,
16% no change and 23% weight loss. Although there was a
trend favouring the higher dose of MA, overall analysis
however failed to detect any statistically significant difference
between the two treatment arms (P=0.242).
When the effect of MA on pain was analysed, we observed
that seven patients out of 23 (30%) with pain in group A
experienced a pain reduction of some intensity after therapy
with MA as compared with five out of 18 patients (27%) in
group B. Energy was improved in 16 out of 41 patients
(39%) with low energy at entry in group A and in 16 out of
35 patients (46%) in group B. Depression improved in nine
out of 36 patients (25%) in group A and in 12 out of 39
patients (31%) in group B. These differences did not reach
statistical significance. Karnofsky index was not apparently
influenced by the positive effects of MA. In fact, performance
status progressively decreased in all patients most probably
owing to progression of cancer.
Dose escalation study
In accordance with the study design, patients who did not
respond to the starting dose of progestin received an increase
of MA of 160 mg day-'. Twenty-seven patients pretreated
with 160 mg day-' and 23 patients treated with
320 mg day-' received further therapy with MA 320 and
480 mg day-' respectively. Results are depicted in Table IV.
Twenty-seven patients unresponsive to MA 160 mg day-'
received 320 mg day-', and 23 patients unresponsive to MA
320 mg day-' received MA 480 mg day-' in three refracted
doses. In the group treated with 320 mg day-', five patients
were not evaluable owing to early death or simultaneous
corticosteroid treatment. Among the 22 evaluable patients,
four (18%) reported an increase in body weight, eight (36%)
an improvement in appetite, but none had an increase in
performance status. On the other hand, three patients were
not evaluable in the group treated with 480 mg day-'.
Among the 20 evaluable patients, two (10%) had an increase
in body weight, four (20%) an improvement in appetite, but
none reported an increase in performance status.
Survival
The median survival was 4.3 months and 5.0 months
respectively for group A and group B. Statistical analysis of
survival showed no significant difference between the two
arms (P=0.43).
Toxicity
Patients were interviewed bimonthly regarding any side-effect
that could be related to the assumption of MA. Peripheral
oedema was recorded in 11 out of 62 patients (18%) treated
at 160 mg day-' of MA and in nine out of 60 patients (15%)
treated at 320 mg day-'. Venous thrombosis was recorded in
four patients (6%) in group A and in three patients (5%) in
group B. Severe pruritus was observed in one female patient
in group B. Nausea and/or vomiting were observed only in
two cases in group A and three patients in group B.
Gastrointestinal intolerance was seen in one female patient
on 320 mg day-'.
The usefulness of MA in the management of ACS has been
demonstrated beyond any doubt by several randomised trials
employing a control arm with placebo (Bruera et al., 1990;
Table M Effect of megestrol acetate on patients' weight according to dose levels and duration of treatment
Treatment with megestrol acetate
15 dais of MA 30 days of MA
160mgday 320mgday 160mgday - 320mgdav 1
(no. ofpatients = 62) (no. ofpatients - 60) (no. ofpatients = 61) (no. ofpatients = 58)
Weight No. (%0 No. (O%) No. No. (%)
Increased 17 (27) 24 (40) 19 (31) 26 (45)
Stable 15 (24) 11 (18) 15 (25) 9 (16)
Decreased 32 (52) 25 (42) 27 (44) 23 (40)
Drop-out 0 0 1 (02) 2 (03)
P = 0.280 P = 0.242
Drop-outs were due to cancer-related death or reduction in patients' compliance.Megestrol acetate in cancer-reated cachexia
V Gebbia et al
Table IV Effect of MA dosage increase in patients w-ho did not
respond to previous therapy with MA
fegestrol acetate dosage
Clinical
variables
Not evaluable
Death
Protocol
ViolationC
Evaluable patients
Weight
Increased
Stable
Decreased
Appetite
Increased
Stable
Decreased
PS
Increased
Stable
Decreased
320mgda -1 480mgdai
1
,no. of patients = 2 a no. of patients = 3,
Na. °,0 Yo. °/0 ,
(18)
(11)
(4)
(100)
4
4
14
8
3
11
0
8
14
(18)
(18)
(64)
(36)
(14)
(50)
(0)
(36)
(64)
(13)
20 (100)
17
4
14
0
15
(10)
(5)
(85)
(20)
(10)
(70)
(0)
(25)
(75)
aPatients treated with MA 160mg day -xwho showed a decrease in
body weight (independently ofappetite) received a supplement of MA
up to 320mgday% and u-ere then followed up for further 30 days.
'Patients treated with MA 320 mgday- who show-ed a decrease in
body weight (independently ofappetite) receixed a supplement of MA
up to 320mgday and were then follow-ed-up for further 30 days.
cSimultaneous treatment with corticosteroids.
Loprinzi et al.. 1990: Feliu et al.. 1992: Tchekmedyan et al..
1992b). However. the optimal dose of MA for the manage-
ment of ACS in patients With advanced cancer has yet to be
definitely determined.
This prospective randomised study was carred out With
the aims of exvaluating the effectiveness of txxo different doses
of MA on weight gain and appetite stimulation in cancer
patients With ACS. and of testing if a further increase in MA
dosage in patients pretreated with MA could result in a good
clinical response. Results achieved after 30 days of therapy
showed that 68% of patients enrolled in the higher dose arm
(320 mg day-') had an increase in appetite as compared With
55% of responders in the group of patients treated with the
lower dose (160 mg day- ). Although there was a trend
toward increased appetite in patients treated w-ith MA
320 mg day-'. this difference did not hoxxexer reach
statistical significance. Again, an increase in body weight
was more frequently obserx-ed in the group of patients treated
With MA 320 mg day-' than in those treated with
160 mg day`. Although there was a trend faxvouring the
higher dose. this difference u-as also not statisticallx
sigmnficant.
These data confirm the effectiveness of MA in treating
tumour-related ACS and are consistent with those reported in
other trials. Lopnrnzi et al. (1993) carried out a randomised
trial on more than 300 patients treated at four different dose
levels of MA and reported a positive dose-response effect of
MA on appetite and food intake, which howxever plateaued at
the dose of 800 mg day-1. A trend in body weight gain was
also recorded. but it did not reach statistical significance.
Recently. simnilar results have been achieved by Parnes et al.
(1994) in a larger series of 380 patients treated with MA 160.
625 and 1250 mg day- while the study by Tattersall et al.
(1994) on 240 patients has reported that MA can significantl-
improve patients appetite. quality of life and mood but has
no effect on their nutritional status. However, in interpreting
these data it should be stressed that patient populations
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included in the aboxe reported trials differ significantly in
terms of response analysis and elegibility criteria such as the
inclusion of patients on cytoreductixve therapies. Our data are
also in accord with those reported by other authors xx-hich
failed to find a strong statistically significant correlation
betx-een MA dosage and its clinical effects on ACS. w-ithout
significant differences betw-een 480 and 960 mg day'
(Schmoll. 1992). The reports by both Loprinzi et al. (1993)
and Schmoll (1992). on the basis of a cost-benefit analI sis.
concluded that the most reasonable therapy for ACS w-ould
be to start With the lou-est possible dose of MA. This is also
confirmed by the observation of bodv >-eight gain in a
significant proportion of women 'ith breast cancer taking
only MA 160 mg day-1 (Willemse et al.. 1990: Abrams et al..
1992).
Interestingly. in our study a small. but significant.
proportion of patients >x-ho did not respond to either doses
of MA responded when MA dosage xx as increased b-
160 mg day '. In fact. among 27 patients x-ho did not
respond to previous therapy w-ith MA 160 mg day' and
xxere subsequently treated with 320 mg day '. five patients
showed an increase in body w-eight and eight patients had an
improxvement in appetite. In accordance A-ith the data
reported by other authors (Feliu et al.. 1992: Tchekmedyian
et al.. 1992a; Loprinzi et al.. 1993). the results achiexed in the
present study suggest that the majority of patients w-ill
respond to the MA lower dose of 160 mg day '. How-exer.
since a relatively small proportion of patients may respond
when a 2- or 3-fold increase in MA dosage over
160 mg da-l is gix-en. treatment of ACS w-ith MA may be
tailored to individual patients. In other w-ords, it seems
rational to start with the lowxer dose of 160 mg day-1 and
subsequently increase the dosage in case of non-response or
stabilisation. or depending on the extension of disease. the
presence of massiv-e visceral metastases and patients' general
conditions. as also suggested by other authors (Heckmayr
and Gatzmeier. 1992: Tchekmedyian et al.. 1992b; Loprinzi et
al.. 1993). The above reported considerations lead us to
conclude that an increase of MA dosage over 480 mg day%
may be useless especially if weighted against cost in terms of
both patients' compliance and quality of life and budgetar-
impact.
Another notewxorthly point is the length of MA treatment.
Data on the effects of MA on body A-eight reported in our
study show- that after only- 15 days of therapy an
improvement in body- >-eight is achiexed in 2700 and 400o
of patients treated respectively at 160 and 320 mg day'.
After 30 days of MA these rates increase to 31°o and 450o
with onlx a 4-5`0 improvement over data achiexved after
only 15 dayvs of treatment. These data suggest that in
tailoring the MA therapy to patients' needs MA could be
stopped or its dosage could be adjusted after only 15 days of
treatment since the majority of responding patients can be
detected after only 2 x-eeks of MA. These data are in accord
wvith the pharmacokinetic characteristics of MA. %x-hich showx
a rapid peak in plasma concentrations after only 7 days of
therapy (Miller et al.. 1988).
Ox-erall. the tw-o different doses of MA employed in our
study have been quite wxell tolerated by most patients. Most
of the adxverse exvents x ere mild and predictable. and no
significant difference in the incidence and sexverity of side-
effects was seen between the twxo groups of treatment.
In conclusion. the data presented in the present study
confirms the clinical safety and effectiveness of oral megestrol
acetate in the management of anorexia cachexia sx-ndrome
in patients with adxvanced cancer resistant to sy-stemic
chemotherapy. Moreoxver. data concerning the dose escala-
tion of MA dosage in unresponsixve patients suggest that a
step-by-step increase in MA dosage wxould be the best wxav of
administering MA for the manazement of ACS and that
increases of MA dosage oxer 480 mg day--' xvill probably be
useless in the xvast majority of cases.
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